Inflammation as a Clinical Endpoint in CKM: Are We There Yet?

As understanding of cardiovascular-kidney-metabolic (CKM) syndrome evolves, inflammation has emerged as a compelling biological thread connecting disease progression across the heart, kidneys and metabolic system. A long-standing question for the field is resurfacing: does chronic systemic inflammation drive disease progression across the CKM spectrum, or has the science outpaced the clinical evidence?

This evolving science raises important questions for clinicians, researchers and industry stakeholders that this webinar will explore: Should inflammation be considered a distinct therapeutic target in CKM? Could it serve as a meaningful clinical endpoint?

The featured speakers will address the specific challenges involved in translating mechanistic understanding into a validated clinical endpoint, including how emerging evidence is reshaping the understanding of this “silent” and often underrecognized driver of disease.

Emerging evidence points to a plausible progression suggesting inflammation may act as a connective thread running through diseases, from obesity to insulin resistance, to vascular inflammation, to kidney dysfunction, to heart failure, that have traditionally been managed as separate, organ-specific concerns. The experts will walk through this proposed pathway and examine why inflammation is increasingly viewed as a cross-system process rather than an isolated biological mechanism.

Attendees will hear how researchers and clinicians are approaching the assessment of inflammation in CKM patients today, including which biomarkers and immune mechanisms are being explored and the specific obstacles that have made inflammation so difficult to translate into a validated, measurable clinical endpoint.

As healthcare moves toward more integrated models of care, this webinar will examine what the current evidence means for trial design, patient selection, biomarkers and endpoint strategy across cardiovascular, renal and metabolic diseases.

The goal is to help development leaders assess where inflammation is actionable today, where evidence remains insufficient and what advances could change its role in CKM clinical development.

Register for this webinar to learn how CKM research is evaluating inflammation as a therapeutic target, biomarker and potential clinical endpoint.

Speakers

Anup Sabharwal, MD, MBA, FACC, FACE, FESC, FAHA, FASPC, FNLA, Head of Research & Development, Cardiovascular-Kidney-Metabolic, Syneos Health

Anup Sabharwal serves as Head of Research & Development, Cardiovascular-Kidney-Metabolic (CKM) at Syneos Health. A board-certified Physician-Scientist specializing in cardiology, endocrinology, diabetes, metabolism and lipidology, he brings more than 20 years of experience across clinical practice, medical affairs, clinical development and scientific strategy. Prior to joining Syneos Health, he held multiple leadership roles at Novo Nordisk, including Head of US Mergers & Acquisitions Scientific Advisory.

Message Presenter

James Snyder, MD, Medical Strategist, Medical Management, Cardiovascular-Kidney-Metabolic, Syneos Health

James Snyder is a Medical Strategist within the Cardiovascular-Kidney-Metabolic (CKM) team at Syneos Health. He is an experienced Physician and Medical Affairs leader with nearly 15 years at Novo Nordisk, where he served in roles including Medical Director, Scientific Director and Medical Scientist. His expertise spans cardiometabolic disease, clinical trial strategy, scientific communications, medical education and business development.

Message Presenter

Tristan Baldwinson, Therapeutic Area Head, Cardiovascular-Kidney-Metabolic, Syneos Health

Tristan Baldwinson is Therapeutic Area Head for Cardiovascular-Kidney-Metabolic (CKM) at Syneos Health. With extensive leadership experience in the biopharmaceutical services industry, he works with global teams to help clients’ advance therapies across cardiovascular, kidney and metabolic diseases. His expertise includes strategic program leadership, therapeutic development and fostering collaboration across clinical, medical and commercial functions.

Message Presenter